Dokument

Eviplera

2012-03-05 15:20
Bzmwnzdffxg5bbbggshg

Creative Commons navngivelse

Download

Pdf Download dokumentet

Creative Commons navngivelse

Kategorisering

Emner:
Epidemier
Medicin
Medicin, lægemidler
Medicinsk forskning
Sundhed, sundhedsvæsen, lægemidler
Sundhedspleje, sundhedsvæsen
Sygdomme

Relaterede pressemeddelelser

Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat

2012-07-03 09:36 Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.

Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients

2012-06-29 13:22 Elvitegravir Also a Component of Quad Single Tablet Regimen, Currently Under Regulatory Review for Patients New to Therapy

U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV

2012-04-11 08:54 -- Viread Now Available in an Oral Powder and Three Lower-Strength Tablets --

U.S. FDA Accepts New Drug Application for Gilead's Once-Daily, Single-Tablet Quad HIV Regimen

2012-04-02 14:51

Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection

2012-04-02 14:50 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults, submitted on November 24, 2011, has been validated by the European Medicines Agency (EMA).

Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada® for Reducing the Risk of Acquiring HIV

2012-03-26 10:21 - If Approved, Product Would Represent First Antiretroviral Indicated to Reduce Risk of HIV Infection in Adults -

Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV

2012-03-26 10:19 - Company to Submit U.S. Regulatory Filing for Elvitegravir in Second Quarter of 2012 -

Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis

2012-03-20 10:16 - Gilead's $8 Million Donation of VL Treatment AmBisome(R) Will Reach 50,000 People in Resource-Limited Countries -

Gilead's Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study

2012-03-20 10:14 - Cobicistat is a Component of Company's Quad Single-Tablet Regimen, Currently Being Reviewed by U.S. FDA -

GILEAD’S QUAD SINGLE TABLET REGIMEN FOR HIV NON-INFERIOR TO ATRIPLA® IN PIVOTAL PHASE 3 STUDY

2012-03-12 15:52 -- Quad Currently Under Review for Marketing Approval by U.S. and European Regulatory Agencies --

Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion

2012-03-12 15:34 - Accelerates Development of All-Oral Regimen for the Treatment of HCV - - Leverages Gilead's Infrastructure and Expertise in Antiviral Drug Development, Manufacturing and Commercialization -

Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV

2012-03-12 15:32 Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ(R) (atazanavir sulfate) and Gilead's cobicistat.

Se flere (12)